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EVIDENCE BASED NEURO-ONCOLOGY
Tumour Treating Fields (TTFs) for Paediatric Brain Tumours, Brain Metastases and
other Novel Applications
Farhan Arshad Mirza1, Muhammad Shahzad Shamim2

Abstract
Tumour treating fields (TTFs) are now FDA approved for
high grade glioma treatment. Novel application of this
treatment modality is being assessed for paediatric brain
tumours and intracranial metastatic disease. Clinical trials
are being conducted to test the efficacy of this treatment
modality as adjuvant therapy to current standard of care.
Here we will discuss the existing literature on TTF its role
in pathologies other than GBM. In addition, aspects of
safety, compliance and cost are also discussed.
Keywords: Brain Metastasis, Tumor Treating Fields,
Alternating Electric Fields, Progression Free Survival,
Overall Survival.

Introduction
In 2004, Kirson and Palti et al., hypothesized that
alternating electric fields at the right frequencies would
disrupt mitotic activity in cancer cells. 1 In 2007, they
described the safety and efficacy of alternating electric
fields of low intensity and intermediate frequencies on
dividing cells in vitro and in vivo. In their experiments,they
noted that externally applied transducer arrays significantly
inhibited the growth intradermal melanoma (B16F1) in
mice and intracranial glioma (F-98) in rats within one week
of treatment. At 100-300 kHz, the alternating currents
affect the mitotic spindle microtubules resulting in
dielectrophoretic movement of molecules during
anaphase and telophase, resulting in cellular disruption
and apoptosis. The electric field strength of the treatment
and its correlation with extent of tumour disruption has
been shown in in vitro studies.2 Only the dividing cells are
affected while the quiescent cells are spared.
The role of TTF in recurrent and newly diagnosed GBM is
well recognized, and we have now begun to explore this
treatment option for other brain tumours. However, other
than efficacy, a major concern remains the safety,
compliance and the cost of treatment, which has raised
1Department of Neurosurgery, Kentucky, USA.
2Department of Neurosurgery, Aga Khan University Hospital, Karachi, Pakistan.

Correspondence: M. Shahzad Shamim. e-mail: shahzad.shamim@aku.edu
Vol. 68, No. 11, November 2018

the argument that TTF remains largely impractical for
majority of patients.
Review of Evidence
We queried the PubMed database with the phrases
'tumour treating fields in brain tumours' and 'alternating
electric fields in brain tumours'. Abstracts of articles
describing this treatment modality were reviewed. Articles
addressing use of tumour treating fields for metastatic
lesions were reviewed. Case reports were included if they
were addressing a novel use of this tool.
Role in Paediatric Brain Tumours
In the paediatric brain tumour population, clinical trials
are under way to better understand the effects of TTFs on
recurrent high grade gliomas and ependymomas.3 One
case report is present in the current literature of a 13-year
old patient with GBM who progressed through surgical
resection, radiotherapy and chemotherapy. TTFs were
used with subsequent stable disease observed
radiographically and clinically for 7 months without any
adverse effects.4 Most recently, a case series of five patients
with high grade gliomas was published by Green et al,
with good tolerability and no treatment limiting toxicity
noted.5 In its current form and application, the use of TTF
is greatly limited in paediatric patients due to compliance.
Role in Brain Metastases
The METIS trial is currently looking at patients with recent
diagnosis of intracranial metastatic lesions, numbering 110, from non-small cell lung cancer, in addition to standard
treatment with stereotactic radiosurgery.6 The COMET
trial recently closed, focusing on the same disease pattern.7
A group from Denmark is conducting a phase I feasibility
trial, looking at the effects of small craniectomy or burrholes in enhancing the delivery of the tumour treating
fields.8 In their pre-clinical computational work, Korshoej
et al showed that removal of a craniotomy flap increased
the strength of the electric fields upto 70% in the tumour,
and caused growth arrest or regression in approximately
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50% of the tumour tissue.9 They also noted that multiple
small burr-holes were more effective than a single
craniotomy. They concluded that a large part of the tumour
should be located relatively close to the surface, it should
be feasible to place a craniectomy or burr-holes
immediately overlying the tumour, and TTF electrodes
should be applied in close vicinity to the surgically made
bony opening. It will be interesting to see the results of
this trial in delivering enhanced treating fields to the
tumour.
Other Potential Applications
Several trials are currently underway, not only for brain
metastasis but also for solid organ tumours (LUNAR,
STELLAR, INNOVATE, PANOVA).10-13 Trials are also underway
to assess the safety and feasibility of TTFs in recurrent
high grade meningiomas as well as low grade gliomas.14
Safety, Compliance and Cost
The treatment modality offers very minimal toxicity profile
compared to chemotherapy and radiation. The device is
supposed to be worn continuously (>18 hrs/day) as the
anti-tumour effects are halted immediately when the
therapy is stopped. At least 4 weeks of continuous
application is needed to halt/reverse tumour growth. The
device delivers electric currents set at a frequency of 200
kHz, is applied to the patient's shaved scalp in a transducer
array which is specified by the treating Oncologist. It is
monitored by device specialists available around the clock
for technical assistance.Guidelines are now available for
Oncologists and patients to make treatment plans based
on imaging findings.15
Compliance rates with therapy have been shown to
directly correlate with overall survival (>75% (>18 hours
daily) versus those with a <75% compliance rate (7.7 v 4.5
months. P=0.42).16 Contact dermatitis can develop, and
can be treated with topical steroids and good hygiene.
Patients have to be instructed on scalp preparation and
care.
Despite the advantages this treatment modality appears
to offer, the costs are prohibitive, especially in an
underdeveloped/developing country setting. Costs have
been estimated to be approximately $20-23,000/month.17

Conclusion
Although TTF is now recognized as a potentially useful
treatment modality for patients with GBM, its role remains

F.A. Mirza, M.S. Shamim

less clear in other forms of brain tumours. However, several
clinical trials are underway and their results are eagerly
awaited. As it is required to be worn for more than 18
hours a day, for 4-weeks, its use appears limited due to
compliance, especially in children. Cost is also a limiting
factor, although as is true for all technological advances,
it is likely to improve substantially with time.
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